lung-cancer

Documents about lung-cancer

• The impact of facilitating patient involvement on decisional conflict among patients undergoing surgical treatment for lung cancer: the serial mediating roles of hope level and social support.#381071NCBI PubMed Central
• Effectiveness of mindfulness-based stress reduction in managing fatigue, anxiety, and depression among non-small cell lung cancer patients receiving surgery and adjuvant chemotherapy: A randomized controlled trial.#590NCBI PubMed Central
• Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!#178212HAL (France)
• Innovative approaches for lung cancer screening and interception.#194327Figshare
• Predictive value of baseline levels and early dynamic changes of ctDNA for 28-day mortality in ICU patients with advanced lung cancer: a prospective single-center cohort study.#351496NCBI PubMed Central
• Nomogram integrating MRI radiomics and white matter hyperintensity grading for predicting overall survival in patients with non-small cell lung cancer and brain metastases receiving whole-brain radiotherapy.#402596NCBI PubMed Central
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417849Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417850Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417851Figshare
• Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer#417852Figshare
• Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4(+) neutrophils and S100A8(+) monocytes.#135901NCBI PubMed Central
• Predictive value of the prothrombin time-to-albumin ratio for 28- and 90-day mortality in lung cancer patients admitted to the intensive care unit: A retrospective cohort study.#251344NCBI PubMed Central
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)#268024ClinicalTrials.gov
• A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement#315132HAL (France)
• Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model#345346OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy#249605ClinicalTrials.gov
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)#279487ClinicalTrials.gov
• The Counseling and Shared Decision-Making Visit for Lung Cancer Screening: A Thematic Analysis of Public Comments to the Centers for Medicare & Medicaid Services During the 2021-2022 National Coverage Analysis Process.#258299NCBI PubMed Central
• Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study#332757ClinicalTrials.gov
• Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in <i>Egfr</i> ‐mutated lung cancer#348396OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer#374506HAL (France)
• Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial#414785Europe PMC
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors#180367ClinicalTrials.gov
• Supplementary Material for: Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer With Sequential ALK Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature#329785Figshare
• Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial#349967ClinicalTrials.gov
• Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis#7722HAL (France)
• Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study#14270HAL (France)
• Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to screen in the Australian National Lung Cancer Screening Program.#154221NCBI PubMed Central
• Predictive value of baseline eosinophil counts for immune-related adverse events in metastatic NSCLC treated with immune checkpoint inhibitors#386527ARPHA OAI-PMH Endpoint
• Table 1_Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy.docx#210838Figshare
• Fabrication of a Multifunctional CoFe₂O₄@BSA@Ag Nanocomposite: A Novel Biocompatible Nanoplatform for Lung Cancer Therapy and Antibacterial Applications#268268Figshare
• Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer#406912Springer Nature OA
• Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer#429747ClinicalTrials.gov
• Global, regional and national burden of tracheal, bronchus and lung cancer attributable to occupational carcinogens from 1990 to 2021 and projections to 2050: A finding from the global burden of disease study 2021 and Mendelian randomization.#165757NCBI PubMed Central
• Impact of the COVID-19 pandemic on diagnosis, and healthcare utilization, among patients with cancer (lung, breast, and pancreas) and cardiovascular diseases (HF, AF, hypertensive, and chronic ischemic heart disease) in Germany: two systematic reviews.#220920NCBI PubMed Central
• Evaluating The Direct Medication Costs Associated With Advanced Non-Small Cell Lung Cancer (nsclc) Treatment By Biomarkers In The United States: A Coarsened Exact Matching Retrospective Cohort Study#260903EliScholar
• Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan’s Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer#397220Springer Nature OA
• Chain mediating effects of self-efficacy and social support on the relationship between engagement in an internet-based traditional Chinese medicine nursing program and quality of life among lung cancer patients: a cross-sectional questionnaire study.#232151NCBI PubMed Central
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies#256861ClinicalTrials.gov
• Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD#326525IRIS
• Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26#299205Springer Nature OA
• A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer#215397HAL (France)
• A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation#435749ClinicalTrials.gov
• First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)#333826HAL (France)
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study#411390ClinicalTrials.gov
• The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)#417530ClinicalTrials.gov
• PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes#320317IRIS
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies#279529ClinicalTrials.gov
• Evidencia sobre el uso de tomografía computarizada de baja dosis en la detección oportuna de neumoconiosis como método de screening en trabajadores expuestos a asbesto#277439Repositorio Universidad Peruana Cayetano Heredia
• AI and Machine Learning in Healthcare and Biomedical Engineering#261682DOAB PROD Instance